| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1371823 | Bioorganic & Medicinal Chemistry Letters | 2012 | 5 Pages |
Abstract
Efforts to modify the central proline portion of lead compound 4 lead to the discovery of novel prolylcarboxypeptidase (PrCP) inhibitors. Especially, replacement with alanine afforded compound 19 displaying more potent human and mouse PrCP inhibitory activity than 4 and an overall comparable profile.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Zhicai Wu, Cangming Yang, Yusheng Xiong, Zhe Feng, Matthew Lombardo, Andreas Verras, Renee M. Chabin, Suoyu Xu, Xinchun Tong, Dan Xie, Mike E. Lassman, Urmi R. Bhatt, Margarita M. Garcia-Calvo, Wayne Geissler, Zhu Shen, Qing Chen, Ranabir Sinharoy,